Intra-Cellular Therapies ... (ITCI)
Intra-Cellular Therapies Statistics
Share Statistics
Intra-Cellular Therapies has 106.52M shares outstanding. The number of shares has increased by 0.9% in one year.
| 106.52M |
| 0.9% |
| 0.48% |
| 91.2% |
| n/a |
| 15,527 |
| 0.43% |
Short Selling Information
| n/a |
| n/a |
| n/a |
| n/a |
Valuation Ratios
The PE ratio is -115.34 and the forward PE ratio is null. Intra-Cellular Therapies's PEG ratio is 2.28.
| -115.34 |
| n/a |
| 12.65 |
| 4.2 |
| 7.5 |
| -117.19 |
| 2.28 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Intra-Cellular Therapies.
| n/a |
| n/a |
| n/a |
| n/a |
Financial Position
The company has a current ratio of 6.36, with a Debt / Equity ratio of 0.01.
| 6.36 |
| 6.23 |
| 0.01 |
| -0.15 |
| -0.23 |
| 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| n/a |
| n/a |
| n/a |
| $791,688.37 |
| $-86,832.56 |
| 860 |
| 0.5 |
| 2.17 |
Taxes
| 473K |
| -0.64% |
Stock Price Statistics
The stock price has increased by 80.35% in the last 52 weeks. The beta is 0.46, so Intra-Cellular Therapies's price volatility has been higher than the market average.
| 0.46 |
| 80.35% |
| 129.42 |
| 92.67 |
| 84.54 |
| 3,621,742 |
Income Statement
In the last 12 months, Intra-Cellular Therapies had revenue of 680.85M and earned -74.68M in profits. Earnings per share was -0.72.
| 680.85M |
| 623.89M |
| -116.72M |
| -74.68M |
| -116.72M |
| -116.72M |
| -0.72 |
Balance Sheet
The company has 306.95M in cash and 16.98M in debt, giving a net cash position of 289.97M.
| 306.95M |
| 16.98M |
| 289.97M |
| -1.69B |
| 1.37B |
| 1.1B |
Cash Flow
In the last 12 months, operating cash flow was -73.18M and capital expenditures -322K, giving a free cash flow of -73.5M.
| -73.18M |
| -322K |
| -73.5M |
| -0.71 |
Margins
Gross margin is 91.63%, with operating and profit margins of -17.14% and -10.97%.
| 91.63% |
| -17.14% |
| -10.9% |
| -10.97% |
| -17.14% |
| -17.14% |
| -10.8% |
Dividends & Yields
ITCI does not appear to pay any dividends at this time.
| n/a |
| n/a |
| n/a |
| n/a |
| n/a |
| n/a |
Analyst Forecast
The average price target for ITCI is $132, which is 0.1% higher than the current price. The consensus rating is "Hold".
| $132 |
| 0.1% |
| Hold |
| 10 |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| n/a |
| n/a |
| n/a |
| n/a |
Scores
| 38.03 |
| 2 |